Search research articles
Contact Us
Filters
Showing results (291-300 of 607) with videos related to
Page
of 61
Sort By:
Arthritis & Rheumatology (Hoboken, N.J.)
|
February 4, 2021
Tocilizumab Prevents Progression of Early Systemic Sclerosis-Associated Interstitial Lung Disease
David Roofeh, Celia J F Lin, Jonathan Goldin, et al.
International Journal of Cardiology
|
March 11, 2017
Tadalafil in idiopathic or heritable pulmonary arterial hypertension (PAH) compared to PAH associated with connective tissue disease
Nazzareno Galiè, Christopher P Denton, Fabio Dardi, et al.
Arthritis and Rheumatism
|
July 1, 1997
Scleroderma lung fibroblasts exhibit elevated and dysregulated type I collagen biosynthesis
X Shi-Wen, C P Denton, A McWhirter, et al.
Journal of Cardiovascular Magnetic Resonance : Official Journal of the Society for Cardiovascular Magnetic Resonance
|
October 28, 2021
Reduced exercise capacity in patients with systemic sclerosis is associated with lower peak tissue oxygen extraction: a cardiovascular magnetic resonance-augmented cardiopulmonary exercise study
James T Brown, Tushar Kotecha, Jennifer A Steeden, et al.
The Journal of Biological Chemistry
|
March 30, 2001
Characterization of an evolutionarily conserved far-upstream enhancer in the human alpha 2(I) collagen (COL1A2) gene
T T Antoniv, S De Val, D Wells, et al.
Journal of Cell Science
|
October 14, 2010
Expression of integrin beta1 by fibroblasts is required for tissue repair in vivo
Shangxi Liu, Shi-wen Xu, Katrin Blumbach, et al.
Arthritis and Rheumatism
|
February 20, 1999
Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial
C M Black, A J Silman, A I Herrick, et al.
Rheumatology (Oxford, England)
|
June 23, 1999
Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud's phenomenon
C P Denton, T D Bunce, M B Dorado, et al.
Clinical Rheumatology
|
March 3, 2005
From scleredema to AL amyloidosis: disease progression or coincidence? Review of the literature
Magdalena Dziadzio, Constantinos P Anastassiades, Philip N Hawkins, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
December 2, 2017
Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo-Controlled, Phase II Study
Christopher P Denton, Éric Hachulla, Gabriela Riemekasten, et al.
Page
of 61
Search research articles
Search
Showing results (291-300 of 607) with videos related to
Sort By:
Page
of 61
Arthritis & Rheumatology (Hoboken, N.J.)
|
February 4, 2021
Tocilizumab Prevents Progression of Early Systemic Sclerosis-Associated Interstitial Lung Disease
David Roofeh, Celia J F Lin, Jonathan Goldin, et al.
International Journal of Cardiology
|
March 11, 2017
Tadalafil in idiopathic or heritable pulmonary arterial hypertension (PAH) compared to PAH associated with connective tissue disease
Nazzareno Galiè, Christopher P Denton, Fabio Dardi, et al.
Arthritis and Rheumatism
|
July 1, 1997
Scleroderma lung fibroblasts exhibit elevated and dysregulated type I collagen biosynthesis
X Shi-Wen, C P Denton, A McWhirter, et al.
Journal of Cardiovascular Magnetic Resonance : Official Journal of the Society for Cardiovascular Magnetic Resonance
|
October 28, 2021
Reduced exercise capacity in patients with systemic sclerosis is associated with lower peak tissue oxygen extraction: a cardiovascular magnetic resonance-augmented cardiopulmonary exercise study
James T Brown, Tushar Kotecha, Jennifer A Steeden, et al.
The Journal of Biological Chemistry
|
March 30, 2001
Characterization of an evolutionarily conserved far-upstream enhancer in the human alpha 2(I) collagen (COL1A2) gene
T T Antoniv, S De Val, D Wells, et al.
Journal of Cell Science
|
October 14, 2010
Expression of integrin beta1 by fibroblasts is required for tissue repair in vivo
Shangxi Liu, Shi-wen Xu, Katrin Blumbach, et al.
Arthritis and Rheumatism
|
February 20, 1999
Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial
C M Black, A J Silman, A I Herrick, et al.
Rheumatology (Oxford, England)
|
June 23, 1999
Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud's phenomenon
C P Denton, T D Bunce, M B Dorado, et al.
Clinical Rheumatology
|
March 3, 2005
From scleredema to AL amyloidosis: disease progression or coincidence? Review of the literature
Magdalena Dziadzio, Constantinos P Anastassiades, Philip N Hawkins, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
December 2, 2017
Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo-Controlled, Phase II Study
Christopher P Denton, Éric Hachulla, Gabriela Riemekasten, et al.
Page
of 61